Publications by authors named "Stephanie R Lane"
Reactions of Re(V), tetradentate Schiff base complexes with tertiary phosphines have previously yielded both rearranged Re(V) and reduced Re(III) complexes. To further understand this chemistry, the rigid diiminediphenol (N(2)O(2)) Schiff base ligand sal(2)phen (N,N'-o-phenylenebis(salicylaldimine)) was reacted with (n-Bu(4)N)[ReOCl(4)] to yield trans-[ReOCl(sal(2)phen)] (1). On reaction with triphenylphosphine (PPh(3)), a rearranged Re(V) product cis-[ReO(PPh(3))(sal(2)phen*)]PF(6) (2), in which one of the imines was reduced to an amine during the reaction, and the reduced Re(III) products trans-[ReCl(PPh(3))(sal(2)phen)] (4) and trans-[Re(PPh(3))(2)(sal(2)phen)](+) (5) were isolated.
View Article and Find Full Text PDFUnlabelled: Gastrin-releasing peptide receptors (GRPr) are a member of the bombesin (BBN) receptor family. GRPr are expressed in high numbers on specific human cancers, including human prostate cancer. Therefore, copper-64 ((64)Cu) radiolabeled BBN(7-14)NH(2) conjugates could have potential for diagnosis of human prostate cancer via positron-emission tomography (PET).
View Article and Find Full Text PDFRadiolabeled regulatory peptides for imaging and therapy.
Curr Opin Endocrinol Diabetes Obes
February 2010
Article Synopsis
- The review discusses innovative methods for diagnosing and treating cancers using radiolabeled regulatory peptides.
- It highlights peptide receptor-targeted radionuclide therapy, which specifically targets cancer cells with high receptor expression while minimizing harm to normal tissues.
- The paper emphasizes the importance of assessing treatment toxicity, radiation dosimetry, and the biological characteristics of the drugs to ensure an effective balance between clinical benefits and risks.
Article Synopsis
- The study focuses on a substance derived from breast cancer cells that targets the gastrin-releasing peptide receptor (GRPR) using a radionuclide for imaging and therapy.
- The imaging probe combines a specific peptide with a radionuclide and shows promise in effectively visualizing GRPR-positive tumors in laboratory mice through advanced imaging techniques.
- Results indicate that this imaging agent successfully accumulates in tumors, suggesting its potential as a diagnostic tool and a foundation for developing improved cancer-targeting therapies.
Introduction: Targeted diagnosis of specific human cancer types continues to be of significant interest in nuclear medicine. 99mTc is ideally suited as a diagnostic radiometal for in vivo tumor targeting due to its ideal physical characteristics and diverse labeling chemistries in numerous oxidation states.
Methods: In this study, we report a synthetic approach toward design of a new tridentate amine ligand for the organometallic aqua-ion [99mTc(H2O)3(CO)3]+.
Article Synopsis
- A study investigates bombesin (BBN) as a delivery method for diagnostic probes like 99mTc radiometal to target cancers that over-express gastrin-releasing peptide receptors (GRPr).
- Various amino acid and aliphatic compounds were tested to determine how they affect the targeting agent's ability to bind to receptors and its distribution in tissues.
- The study reveals that some new 99mTc-BBN conjugates show significant effectiveness in targeting prostate cancer tumors in rodent models, suggesting potential for improved cancer imaging techniques.